

Inter IIT Tech-Meet 11.0

# Cognitive Garage-Easy Automation of Complex Decision Making

Team\_ID- 55

\*\*\*

## Index

Serial No.	Content	Page Number
1	<a href="#"><u>Use Case 1: Personalised Consumer Incentive Design in Digitally native brands across the consumer funnel</u></a>	2
2	<a href="#"><u>Use Case 2: Automation of Lead Identification for R&amp;D phase of drug discovery</u></a>	3
3	<a href="#"><u>Use Case 3: Making customised diet plans based on consumer's health and dietary goals</u></a>	4

**Domain:** *Personalised Consumer Incentive Design in Digitally native brands across the consumer funnel*

**Use Case:** Personalising consumer incentives to increase customer **acquisition**, **retention**, and **loyalty**. Consumer incentives can include **reward points**, cashback, **store credits**, branded swag, gift cards, bonuses with free purchases, etc. Aiming at **digitally native brands** since they forge a data backed direct to customer model and lay special emphasis on personalization. (Examples: Lenskart, Nykaa, MamaEarth).

**Complex Decision being automated:**

Deciding **which incentive** to give to the consumer based on a number of personalized parameters:


- **Company goals** (customer acquisition/retention/ increase revenue), **Consumer data** (to understand the demography, purchase history, and consumer behaviour), **Incentive parameters** (types of incentive and amount of incentive)

**What makes this a complex decision and why is there a need for automation?**

- Designing tailor-made customer-market incentives require a lot of manual **effort**, and **time**.
- A higher level of personalization is **nearly impossible** for marketing teams **to achieve manually**.
- By using a marketing strategy that **automatically offers truly personalized incentives**, each customer receives the offer **most likely to convince** them to make a purchase.

**Benefits of automating**

- **Personalization:** [71% of consumers expect](#) companies to deliver personalized interactions.
- **Revenue and Cost Cutting:** [40% more revenue](#) while cutting down [marketing costs by 10-20%](#).
- **Retention and Loyalty:** [81% increase](#) in annual recurring purchases and a [53% increase in brand loyalty](#) were observed in brands prioritizing personalization.



**Domain:** Pharmaceutical Industry

**Use Case:** Implementing our decision-making automation platform in the *lead identification phase of R&D of drug discovery*. This automation process is known as HTS analytics:

- The global high-throughput screening market size is projected to reach [USD 26.4 billion](#) by 2025 from **USD 15.3 billion** in 2020, at a CAGR of **11.5%** during the forecast period.
- The drug discovery segment accounted for the highest CAGR.
- The market in the **Asia Pacific**, on the other hand, is projected to grow with the highest CAGR of [8.6%](#) over the forecast period.

**Complex Decisions being automated:** Accurately forecast the drugability of various compounds to identify the lead for the formulation of drugs based on a number of parameters:


- Interaction with **target receptor**, **physicochemical properties** of the compound, **pharmacokinetics** (how the body interacts with administered substances), and **pharmacologic effect**.

**What makes this a complex decision and why is there a need for automation?**

It involves a lot of parameters as mentioned above to be analyzed and predicted. Pharmaceutical companies find it tough to manually complete this procedure, Data automates this complex decision-making process involved and drastically fastens the drug discovery process.

**Need and Benefits of Automation:** In the [1990s](#), a typical HTS campaign would screen around **10,000** compounds per year. With the introduction of automation and robotics, that number has increased to several million compounds per year.

- **Increased Developmental Cost** - As per [Eroom's law](#), drug development costs double every **9 years**. Surprisingly less than 1/3rd, **31.8%**, of all pre-clinical studies, enter phase one of a clinical trial.
- **Expedited Drug Development** - takes about **10 years** to complete the drug development cycle which may cost somewhere around **USD 2 billion**. We can reduce expenditures and save time in this industry.
- **Recurrent Assay Generation** - Automated assays have a nearly [50%](#) higher hit rate than manual assays.



**Domain:** *Clinical nutritionist industry*

**Use Case:**

The global clinical nutritionist industry is valued at [\\$ 11.7 Billion](#) and has a CAGR of 8.8 % for the next 5 years. Given the **dependence** of *diet planning* on the input parameters of the consumers, this decision of scoring and prioritising blocks of diet plans to create *a customized and consolidated diet plan* will be automated creating more **dynamic structures**.

**How this solves a complex problem:** Decide what kind of dietary plan is best suited to meet the consumer's lifestyle and health requirements based on a number of parameters:

- **Linearly structured primary parameters**, majorly concerned with **medical condition**
- **Supposedly irrelevant externalities** that affect the decision. For instance, consumer demography, and geographical and availability constraints.

**What makes this a complex decision and why is there a need for automation?**

There are a number of parameters involved to be considered while devising any dietary plan personalized to meet any individual's health and lifestyle requirements. It is not possible for a human to manually access and consider all these parameters and devise such a plan.

**Need and Benefits of automation:**

- **Minimizing time and optimizing accuracy:** AI automation would free up [70%](#) of the time used for tasks and routine management.
- **Cost Efficiency:** Automation would reduce overhead costs by more than [10%](#).
- **Dynamic Personalisation of variables:** [88%](#) of the population requires personalization as a necessary factor for the nutritional plans in terms of changing variables.

